FeesSafety
Pluang+

Harrow Inc. nears $350M 2026 revenue goal after strong Q3 growth and expanded sales efforts.

Market News
16 Nov 2026, 09:31 WIB
Seeking Alpha
View Source
Bullish
Harrow Inc. nears $350M 2026 revenue goal after strong Q3 growth and expanded sales efforts.

Harrow Inc., a Nashville-based ophthalmology company, showed strong Q3 performance with significant quarter-over-quarter growth in its products VEVYE (up 35%) and IHEEZO (up 62%). The company is expanding its commercial coverage and sales team, which is improving average selling prices and market share for VEVYE. If Harrow maintains momentum in Q4 and gains approval for its G-MELT drug, its stock could potentially double by 2027. This positions Harrow well to reach its ambitious $350 million revenue target by 2026 while keeping R&D costs low through a licensing and sales strategy.

Harrow Inc.'s strong revenue growth and operating leverage outlook provide context for readers. For those following the Health sector, here is Pluang's market snapshot as of Nov 16, 2026 14:02 WIB: Among 150 priced US Health-sector stocks tradable on Pluang, 54 rose and 93 fell today. Notable movers include ERAS (Erasca Inc. Common Stock) at USD 15.66 with a 1-day change of -6.79% and a typical hold time of 4 days, MDLN (Medline Inc. Class A Common Stock) at USD 39.47 down 6.38% with a 7-day hold, and HRTX (Heron Therapeutics Inc) at USD 0.33 up 6.28% with a typical hold time of 39 days.

More News

Lakefront Biotherapeutics launches new €50M share buyback after completing initial program

Lakefront Biotherapeutics launches new €50M share buyback after completing initial program

Lakefront Biotherapeutics has started a new €50 million share buyback program following the completion of its initial €50 million program, in which it repurchased about 1.99 million shares. The new program, running until March 31, 2027, aims to enhan...

Company Fundamentals
Bullish
1 hour ago
Exosens wins order for 25,000 image intensifier tubes to boost European night vision tech.

Exosens wins order for 25,000 image intensifier tubes to boost European night vision tech.

Exosens secured a firm order to supply 25,000 high-performance 4G+ image intensifier tubes to Theon Sensors for integration into night vision devices, with deliveries starting late 2026. This order is part of a long-term agreement through 2030 and in...

Market News
Bullish
1 hour ago
Exosens secures a major order for 25,000 light intensifier tubes for night vision devices through 2030.

Exosens secures a major order for 25,000 light intensifier tubes for night vision devices through 2030.

Exosens has received a firm order for 25,000 high-performance 4G+ light intensifier tubes to equip night vision products for Theon, under a long-term supply agreement extended through 2030. The order includes options for an additional 35,000 tubes, p...

Market News
Bullish
1 hour ago
Jyske Bank buys back 2.45M shares worth DKK 2.39B, owning 4.22% of its stock by Nov 2026.

Jyske Bank buys back 2.45M shares worth DKK 2.39B, owning 4.22% of its stock by Nov 2026.

Jyske Bank is conducting a share buyback program running from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-November 2026, the bank has repurchased 2,453,745 shares at an average price of DKK 974.50 per share...

Company Fundamentals
Bullish
2 hours ago
Jyske Bank buys back shares worth DKK 2.39 billion, holding 4.22% treasury shares as of November 2026

Jyske Bank buys back shares worth DKK 2.39 billion, holding 4.22% treasury shares as of November 2026

Jyske Bank has been actively repurchasing its shares under a program running from February 2026 to January 2027, acquiring shares worth up to DKK 3 billion. As of mid-November 2026, the bank has bought back shares valued at approximately DKK 2.39 bil...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App